English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background We continue to make progress on a multi-epitope, crossclade GAIA HIV vaccine [De Groot, Vaccine, 2008, 26: 3059–71]. New evidence from elite controllers supports our original hypothesis that multiple, highly conserved Tcell epitopes in a single HIV vaccine construct will better control HIV infection [Davenport, Immunol Rev., April 2007; Kong, J Virol., March 2009]. We believe that T cellmediated vaccines constructed from highly cross-conserved HIV Th and CTL epitopes will succeed with the benefit of advances in the adjuvant, formulation and delivery areas that will inform better vaccine construction. We have performed several recent studies that also support this hypothesis.

P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success